For anyone who wants to try GLP1s treatment without locking themselves into a contract, MEDVi hits the right balance between affordability and the level of medical support that makes a real difference, especially in the early months of treatment
2
*Correspondence: Roberta Poli, [email protected] These authors have contributed equally to this work and share first authorship This article was submitted to Clinical Diabetes, a section of the journal Frontiers in Endocrinology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Saxenda was launched to market in the United States on April 22, 2015
About the Compound AOD-9604 is a synthetic 16-amino-acid peptide with the sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (YLRIVQCRSVEGSCGF) stabilized by a disulfide bond between the two cysteine residues
A coalition representing nearly 5,000 independent pharmacies has filed an antitrust lawsuit against Prime Therapeutics, alleging it colluded with Express Scripts to suppress pharmacy reimbursement rates and increase fees through a 2019 partnership agreement